

# Motherwort

## Species (Family)

*Leonurus cardiaca* L. and various other *Leonurus* species (Labiatae)

## Synonym(s)

Leonurus

## Part(s) Used

Herb

## Pharmacopoeial and Other Monographs

BHC 1992<sup>(G6)</sup>

BHP 1996<sup>(G9)</sup>

Complete German Commission E<sup>(G3)</sup>

Martindale 32nd edition<sup>(G43)</sup>

PDR for Herbal Medicines 2nd edition<sup>(G36)</sup>

## Legal Category (Licensed Products)

GSL<sup>(G37)</sup>

## Constituents<sup>(G6,G22,G40,G49,G64)</sup>

**Alkaloids** 0.35%. Stachydrine (a pyrrolidine-type alkaloid), betonicine and turicin (stereoisomers of 4-hydroxystachydrine), leonurine 0.0068% (a guanidine derivative),<sup>(1)</sup> leonuridin, leonurinine. The presence of leonurine in *L. cardiaca* has been disputed, although it has been documented for other *Leonurus* species.

**Flavonoids** Glycosides of apigenin, kaempferol, and quercetin (e.g. hyperoside, kaempferol-3-D-glucoside, genkwanin, quinqueloside, quercitrin and rutin).<sup>(2,3)</sup>

**Iridoids** Ajugol, ajugoside, galiridoside, leonurid and three or four more unidentified glycosides.<sup>(4)</sup>

**Tannins** 2–8%. Type not specified. Pseudotannins (e.g. pyrogallol, catechins).

**Terpenoids** Volatile oil 0.05%, resin, wax, ursolic acid, leocardin (a labdane diterpene)<sup>(5)</sup> as an epimeric mixture, and a diterpene lactone similar to marrubiin.<sup>(2)</sup> Cardiac glycosides (bufadienolide/bufanolide

type) have been documented although their presence in motherwort has not been confirmed.

**Other constituents** Citric acid, malic acid, oleic acid, bitter principles,<sup>(6,7)</sup> carbohydrates 2.89%, choline and a phenolic glycoside (caffeic acid 4-rutinoside).<sup>(8)</sup>

A *Cad*-specific lectin has been isolated from the seeds.<sup>(9)</sup>

## Food Use

Motherwort is not used in foods. In the USA, motherwort is listed by the Food and Drugs Administration (FDA) as a Herb of Undefined Safety.<sup>(G22)</sup>

## Herbal Use

Motherwort is stated to possess sedative and anti-spasmodic properties. Traditionally, it has been used for cardiac debility, simple tachycardia, effort syndrome, amenorrhoea, and specifically for cardiac symptoms associated with neurosis.<sup>(G6,G7,G8,G64)</sup>

## Dosage

**Dried herb** 2–4 g or by infusion three times daily.<sup>(G6,G7)</sup>

**Liquid extract** 2–4 mL (1:1 in 25% alcohol) three times daily.<sup>(G6,G7)</sup>

**Tincture** 2–6 mL (1:5 in 45% alcohol) three times daily.<sup>(G6,G7)</sup>

## Pharmacological Actions

### *In vitro* and animal studies

The uterotonic principle in motherwort is unclear, although leonurine is reported to be the utero-active constituent in various *Leonurus* species. In addition, oxytocic activity documented for *L. cardiaca* has been attributed to another alkaloid constituent, stachydrine.<sup>(G30)</sup> Uterotonic activity has been reported for leonurine in various *in vitro* preparations including human myometrial strips and isolated rat uterus.<sup>(10,11)</sup>

*In vitro* cardioactivity has been documented for motherwort.<sup>(12)</sup> An alcoholic extract was found to have a direct inhibitory effect on myocardial cells:

antagonistic action towards calcium chloride (provided that the extract was administered before calcium chloride), and towards both  $\alpha$ - and  $\beta$ -adrenoceptor stimulation was observed. No significant effect on the cardiac activity of the isolated guinea-pig heart was noted for caffeic acid 4-rutinoside.<sup>(8)</sup>

A related species, *Leonurus heterophyllus*, has been stated to prevent platelet aggregation, although no such documented action was located for motherwort.<sup>(13)</sup>

Ursolic acid has been reported to possess antiviral, tumour-inhibitory and cytotoxic activities.<sup>(14,15)</sup> Ursolic acid was found to inhibit the Epstein-Barr virus *in vitro* and to inhibit tumour production by 12-O-tetradecanoyl phorbol (TPA) in mouse skin, with activity comparable to that of retinoic acid, a known tumour-promoter inhibitor.<sup>(15)</sup> *In vitro* cytotoxicity was documented in lymphocytic leukaemia (P-388, L-1210), human lung carcinoma (A-549), KB cells, human colon (HCT-8) and mammary tumour (MCF-7).<sup>(14)</sup>

### Side-effects, Toxicity

It has been stated that the leaves of motherwort may cause contact dermatitis and that the lemon-scented oil may result in photosensitisation.<sup>(G51)</sup> No documented toxicity studies were located. Cytotoxic activities have been reported for ursolic acid (see *In vitro* and animal studies).

### Contra-indications, Warnings

Excessive use may interfere with existing therapy for a cardiac disorder (cardiac glycoside constituents, *in vitro* activity). Sensitive individuals may experience an allergic reaction.

**Pregnancy and lactation** Motherwort is reputed to affect the menstrual cycle.<sup>(G22)</sup> In view of the lack of toxicity data and the documented *in vitro* uterotonic activity,<sup>(G30)</sup> the use of motherwort during pregnancy and lactation should be avoided.

### Pharmaceutical Comment

The common name motherwort may be applied to one of many *Leonurus* species. *L. cardiaca* is the typical European species utilised, whereas *Leonurus artemisia* is commonly used in traditional Chinese medicine. Other species referred to as motherwort include *Leonurus sibiricus* and *L. heterophyllus*. The chemistry of *L. cardiaca* is well studied although the presence of the uterotonic principle leonurine has been disputed. Cardioactive properties in animals

have been reported for motherwort (*L. cardiaca*), which thus support some of the stated herbal uses. However, any symptoms of cardiac disorder are not suitable for self-diagnosis and treatment with a herbal remedy. In view of the lack of toxicity data and possible cardioactivity, excessive use of motherwort should be avoided.

### References

See also General References G3, G6, G9, G22, G30, G31, G36, G37, G40, G43, G49, G51 and G64.

- 1 Gulubov AZ. Structure of alkaloids from *Leonurus cardiaca*. *Nauch Tr Vissb Predagog Inst Plovdiv Mat Fiz Khim Biol* 1970; 8: 129-132.
- 2 Scott JH *et al.* Components of *Leonurus cardiaca*. *Sci Pharm* 1973; 41: 149-155.
- 3 Kartnig T *et al.* Flavonoid-O-glycosides from the herbs of *Leonurus cardiaca*. *J Nat Prod* 1985; 48: 494-507.
- 4 Buzogany K, Cucu V. Comparative study between the species of *Leonurus quinquelobatus*. Part II Iridoids. *Clujul Med* 1983; 56: 385-388.
- 5 Malakov P *et al.* The structure of leocardin, two epimers of a diterpenoid from *Leonurus cardiaca*. *Phytochemistry* 1985; 24: 2341-2343.
- 6 Brieskorn CH, Hofmann R. Labiatenbitterstoffe: Ein clerodanderivat aus *Leonurus cardiaca* L. *Tetrahedron Lett* 1979; 27: 2511-2512.
- 7 Brieskorn CH, Broschek W. Bitter principles and furanoid compounds of *L. cardiaca*. *Pharm Acta Helv* 1972; 47: 123-132.
- 8 Tschesche R *et al.* Caffeic acid 4-rutinoside from *Leonurus cardiaca*. *Phytochemistry* 1980; 19: 2783.
- 9 Bird GWG, Wingham J. Anti-Cad lectin from the seeds of *Leonurus cardiaca*. *Clin Lab Haematol* 1979; 1: 57-59.
- 10 Yeung HW *et al.* The structure and biological effect of leonurine - a uterotonic principle from the Chinese drug, I-mu Ts'ao. *Planta Med* 1977; 31: 51-56.
- 11 Kong YC *et al.* Isolation of the uterotonic principle from *Leonurus artemisia*, the Chinese motherwort. *Am J Chin Med* 1976; 4: 373-382.
- 12 Yanxing X. The inhibitory effect of motherwort extract on pulsating myocardial cells *in vitro*. *J Trad Chin Med* 1983; 3: 185-188.
- 13 Chang CF, Li CZ. Experimental studies on the mechanism of anti-platelet aggregation action of motherwort. *Chung-Hoi-I-Chich-Ho-TSQ Chin* 1986; 6: 39-40.
- 14 Kuo-Hsiung L *et al.* The cytotoxic principles of *Prunella vulgaris*, *Psychotria serpens*, and *Hyptis*

*capitata*: Ursolic acid and related derivatives.  
*Planta Med* 1988; 54: 308.

15 Tokuda H *et al.* Inhibitory effects of ursolic and

oleanolic acid on skin tumor promotion by  
12-O-tetradecanoylphorbol-13-acetate. *Cancer  
Lett* 1986; 33: 279–285.